AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-page health warning leaflet
Description: Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-page health warning leaflet
Description: Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages through Instant Messaging (IM)
Description: A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time chat-based support through IM Apps
Description: The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health through SMS
Description: After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong
Description: a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong
Description: a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women
Study NCT00111670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid or qd
Study NCT00111670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid or qd
Study NCT03263884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive trancranial magnetic stimulation (rTMS) group
Description: Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
Study NCT03263884 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
Study NCT01459510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Nicely Program
Description: Multi media educational intervention
Study NCT02798510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Study NCT02798510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT02798510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT02798510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT02798510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Study NCT04789265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented- assisted soft tissue mobilization (IASTM)
Description: IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
Study NCT00993655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
Study NCT00993655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin 75 mg/m2 intraperitoneal day 1
Study NCT00993655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
Study NCT02314624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality
Description: Evidence-based interventions for treating depression and concurrent problems
Study NCT02314624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care-as-Usual Psychotherapy
Description: Usual care psychotherapy for depression and concurrent problems
Study NCT05590780 — intervention group
Intervention type: OTHER
Intervention: Clinical Attachment level
Description: 1-year
Study NCT00774306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenytoin
Description: Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
Study NCT00774306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproate
Description: Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
Study NCT02096328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study NCT03489304 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zaleplon
Description: non-benzodiazepine hypnotic agent
Study NCT02073799 — intervention group
Intervention type: PROCEDURE
Intervention: Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)
Study NCT02425839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound exam by Supersonic Shear Imaging® technique
Description: Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
Study NCT02425839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG examination by electromyograph Keypoint system
Description: Experimented neurologist performs EMG examination.
Study NCT00950066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IRBESARTAN (SR47436)
Description: Oral administration of Irbesartan 150mg or 300mg once a day
Study NCT00950066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Oral administration of Amlodipine 5mg once a day
Study NCT00950066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan / Amlodipine
Description: Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
Study NCT00950066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of a placebo once a day
Study NCT04134156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: 5-port sleeve gastrectomy
Study NCT04134156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one anastomosis gastric bypass
Description: 5-port one anastomosis gastric bypass
Study NCT03436329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein ligation first
Description: During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
Study NCT03436329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artery ligation first
Description: During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
Study NCT02642250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
Study NCT02642250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entoban
Description: To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
Study NCT03907280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (R)
Description: concentrate for i.v. solution
Study NCT00616187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta treatment to add-on atorvastatin treatment
Description: IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
Study NCT00616187 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: untreated to atorvastatin treatment
Description: no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
Study NCT03603080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of weight loss drug (Metformin or Topiramate)
Description: Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
Study NCT02077348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin withdrawal
Description: Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
Study NCT02077348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: 0,4 mg of GH administered at 7.05 A.M. on the study day.
Study NCT02935491 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used
Study NCT03817996 — intervention group
Intervention type: OTHER
Intervention: Fluid challenge
Description: 250ml of saline in Responders (those who increased >10% their cardiac output after a passive leg raising maneuver).
Study NCT02163733 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD9291 tablets
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Study NCT02163733 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
Study NCT02163733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Fasted
Description: Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
Study NCT02163733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary High Fat
Description: Allocated breakfast prior to dosing with 80mg AZD9291 tablet
Study NCT02163733 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
Study NCT01402141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chungkookjang
Description: Chungkookjang(35g/say)for 12 weeks
Study NCT03907280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T3)
Description: Solution for inhalation
Study NCT04385446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane transplantation
Description: Amniotic membrane transplantation was used as covering material during pterygium surgery.
Study NCT00174642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: One daily injection in the evening. 100 U/ml
Study NCT00174642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Given immediately before each of the three main meals. 100 U/ml
Study NCT00174642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At same dosages as the previous treatment
Study NCT00174642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin secretagogue
Description: sulfonylurea or glinide
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Website access given that allows participant to track exercise behavior and help to set goals.
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Website
Description: Website access given that allows participant to track exercise behavior and help to set goals.
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise DVD
Description: Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake.
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake.
Study NCT01508273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Report Assessments
Description: Self-report assessments given about quality of life and physical assessments of balance and coordination.
Study NCT03828123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suspension of human autologous MSC 3P in 1.5 ml
Description: Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
Study NCT01402141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(35g/day) for 12 weeks
Study NCT00828984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macrogol 3350-based oral osmotic laxative
Description: Given PO
Study NCT00828984 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00828984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00828984 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05079074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA testing
Description: ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
Study NCT03212157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Description: Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
Study NCT03212157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
Study NCT03212157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
Study NCT03214367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03214367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03214367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03214367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03214367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT03214367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study NCT01633879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio-CD parent education
Description: audio CD stories in English and Spanish that support positive parenting practices
Study NCT04805801 — intervention group
Intervention type: DRUG
Intervention: Emicizumab subcutaneous injection
Description: Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
Study NCT01633879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health and success parent and school
Description: Parenting education and school intervention
Study NCT04238364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EI-1071
Description: EI-1071 Tablet(s)
Study NCT00774306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
Study NCT02551471 — intervention group
Intervention type: OTHER
Intervention: Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)
Description: This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries.
Study NCT04238364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet(s)
Study NCT01930357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vero Rabies Vaccine Serum Free (VRVg)
Description: 0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
Study NCT01930357 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),
Description: 0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
Study NCT03676179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patella denervation
Description: patella denervation
Study NCT03676179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patella non-denervation
Description: patella non-denervation
Study NCT01654432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Blocks (PVB)
Study NCT02366637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally inhaled placebo twice a day (BID) for 4 weeks
Study NCT02366637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03715455
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks